<DOC>
	<DOCNO>NCT02960659</DOCNO>
	<brief_summary>Background : The pill metformin treat diabetes . But work youth , especially African-Americans . The injectable Liraglutide treat type 2 diabetes adult . Researchers want understand drug work decrease excess sugar make liver youth type 2 diabetes . Objective : To test use liraglutide metformin well metformin decrease excess sugar produce liver African-American youth type 2 diabetes . Eligibility : African-Americans age 12 21 type 2 diabetes Design : Visit 1 : Participants screen medical history , physical exam , blood urine test . Participants stop take diabetes medicine 1 week . They learn check blood sugar home twice day . Visit 2 : Overnight clinic . Participants : Vital sign take . Pregnancy test . A thin plastic tube ( IV catheter ) insert forearm needle . Blood draw several time drink sweet drink . X-ray total body fat . Urine stool collect . Breath test wear clear hood 45 minute . For several hour , participant water . At 4 a.m. get sugar fat nonradioactive isotope one IV . Blood collect . Every 30 minute 9 a.m. 2 p.m. , drink small amount shake blood drawn . Participants randomly assign take either study drug daily metformin daily . Visits 3 4 : Participants bring blood sugar record blood test . Visit 5 , 3 month : Repeat visit 2 ... .</brief_summary>
	<brief_title>Title : Therapeutic Targets African-American Youth With Type 2 Diabetes</brief_title>
	<detailed_description>Type 2 Diabetes youth emerge public health concern disproportionately affect minority child . Among minority youth , African-Americans high complication rate , yet reason underlie health disparity fully understood . Furthermore , current treatment option limit African-American youth high treatment failure rate . Metformin therapy oral diabetes drug approve use youth type 2 diabetes . However , metformin work less 50 % time African-American youth mark variability among individual . Improving outcome youth require understanding way drug metformin work youth work individual . New evidence suggest ability metformin work effectively may influence certain gene difference gut bacteria . However , little know gene gut bacteria may affect youth , especially African-Americans . To treat aggressive disease , also necessary simultaneously evaluate new therapeutic option , combination therapy metformin liraglutide youth high risk complication . Liraglutide approve treat diabetes adults yet approve child . Liraglutide may useful early treatment youth type 2 diabetes may decrease glucose produce liver ( early prominent feature type 2 diabetes youth ) . This study design examine mechanism action liver 2 agent explore genetic gut factor may influence action . The primary objective pilot study compare ability two anti-diabetic regimen ( metformin liraglutide versus metformin alone ) low gluconeogenesis ( glucose produce liver ) African-American youth type 2 diabetes . The secondary objective evaluate effect regimen follow : ( 1 ) hepatic glucose production , insulin sensitivity ( 2 ) insulin gut hormone concentration ( e.g . incretins ) . In addition , examine relationship know difference gene associate metformin transport action change gluconeogenesis begin explore role gut bacteria metformin glucose-lowering effect . The study design parallel-randomized intervention trial African-American youth type 2 diabetes insulin therapy within 3 year diagnosis . Patients age 12-21 year type 2 diabetes enrol . Participants randomize two intervention arm ( 16 group ) : metformin liraglutide versus metformin alone . The study consist 5 visit . At Visit 1 , medical history , physical examination screen labs do . Then eligible participant undergo one-week drug-free run-in . At Visit 2 overnight inpatient stay perform metabolic test prior start study drug ( ) . Participants start study drug ( ) immediately Visit 2 remain study drug ( ) 12 week . Follow-up monitoring perform 4 week interval ( Visit 3 4 ) . The final visit ( Visit 5 ) occur 12 week . The ultimate goal project begin address diabetes disparity African-American youth understand mechanism action diabetes agent inform precision medicine initiative . This project bring together skill expertise investigator within National Institute Diabetes Digestive Disorders Kidney Diseases ( NIDDK ) , National Human Genome Research Institute ( NHGRI ) Children National Medical Center ( CNMC ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Youth must selfidentify AfricanAmerican identify parent AfricanAmerican 2 . Age 1221 year 3 . Pubertal postpubertal : Girls Tanner stage IVV breast ; Boys Testicular volume 1125cc 4 . Diagnosis type 2 diabetes &lt; 3 year duration 5 . Hemoglobin A1C &lt; 9 % study initiation 6 . Negative mild ketonuria without acidosis ( negative 1+ ketone urinalysis ) 7 . Negative test diabetesrelated autoantibody ( glutamic acid decarboxylase 65 tyrosine phosphataserelated islet antigen 2 ( IA2 ) ) 8 . Willing able take daily medication check blood glucose level least twice per day EXCLUSION CRITERIA : 1 . Pregnancy breastfeed 2 . Allergy study medication 3 . Allergy milk protein 4 . Chronic insulin therapy 5 . Treatment medication know affect parameter study 6 . Metabolic derangement metabolic acidosis , severe hyperglycemia ( fast blood glucose great equal 200mg/dL ) , and/or liver enzyme &gt; three time upper limit normal . 7 . Personal family history medullary thyroid cancer Multiple Endocrine Neoplasia syndrome type 2 8 . Any condition , opinion investigator , increase risk subject , impede accurate collection studyrelated data . 9 . Body weight great equal 450 lb , 10 . Serum triglyceride concentration great equal 500mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 8, 2016</verification_date>
	<keyword>Metformin</keyword>
	<keyword>Glucose</keyword>
</DOC>